Neuralink's Head Neurosurgeon Just Backed a Brain-Cancer Implant Funded by OpenAI's Startup Fund. The Implant Hasn't Gone Into a Patient Yet.

Honest fence (read first): This is a funding story about a different company, Coherence Neuro. It's on Neuralink Sunday because two of Neuralink's own doctors put their own money in, and because Neuralink's biggest early backer co-led the round. It is not a Neuralink product, and Neuralink hasn't commented.

Editorial Thesis

On Wednesday, Oct 21, 2026, Coherence Neuro announced a $45 million Series A co-led by Founders Fund and the OpenAI Startup Fund. The headline that spread was "OpenAI backs a brain implant." The more interesting detail for Neuralink watchers sits lower in the announcement: the angel investors include Dr. Matthew MacDougall, Neuralink's head neurosurgeon, and Dr. Rory Murphy, a Neuralink principal investigator. The people who put Neuralink's N1 into patients are betting that implants can do more than control a cursor. The evidence for this particular bet is still early.

Honest Verdict

Believe the round: the amount, the co-leads and the angel list come from Coherence's own announcement and match Inside BCI's and The BCI Briefing's reporting. Believe that Coherence has started a human study, a short one: a thin film of electrodes laid on the brain for about half an hour during tumour surgery. Don't believe anyone who says a brain implant now treats cancer. The device Coherence wants to leave in the brain, SOMA, hasn't gone into a single patient. The evidence that brain signals can track a tumour comes from mice, in a preprint that hasn't been peer reviewed.

What Coherence actually announced

• $45 million, which Coherence calls its Series A. Co-led by Founders Fund and the OpenAI Startup Fund. (WIRED called it a seed round; Coherence raised a $10 million seed in November 2025.)
• New investors: Lux Capital, 8VC, Timeless, Olive Capital and Ahren. Earlier backers put in more.
• Angels: Neuralink's MacDougall and Murphy, plus others named in the post.
• What the money is for: a first long-term human trial in glioblastoma, an application for FDA Breakthrough Device designation, and early lab work in pancreatic cancer.
• On data: CEO Ben Woodington told WIRED that nothing in the deal gives OpenAI access to brain or health data. The terms behind that promise aren't public.

The two devices, and how far each has got

The science underneath is real. In 2019, Michelle Monje's lab at Stanford showed in Nature that glioma cells form working connections with neurons. Monje is an author on Coherence's July 2026 preprint, in which recordings from implants in mice tracked how much tumour each animal carried. That's a mouse result, and it's the company's own paper.

Why Neuralink people backing it matters

1. It's a vote on the platform. Neuralink's N1 reads motor signals so people can move a cursor or speak. Coherence wants an implant that reads and writes, around a tumour. Two of Neuralink's surgeons choosing to invest says they think brain interfaces will spread beyond paralysis. MacDougall has talked publicly about brain-tumour surgery too (see the Huberman Lab Essentials episode, uploaded Oct 15).
2. The money overlaps. Founders Fund led Neuralink's $280 million Series D in 2023. Now it's co-leading a brain-implant company with OpenAI's venture fund, while Sam Altman's own BCI start-up, Merge Labs, took a direct OpenAI investment in January.
3. What we don't know: how big the angel checks are, and whether Neuralink has a policy on staff investing in other neurotech firms. Neither company has said.

Also this week in Neuralink's field

Paradromics and Siemens Healthineers (Oct 19) said they'll build a standard imaging workflow, from MRI and CT to surgical navigation, for placing brain implants, starting with the part of the brain that controls speech. It's a plan with no financial terms disclosed. Paradromics says it already scans on Siemens machines.

Claim vs proof

What to watch next

• Results from the Melbourne CIPHER study, especially the stimulation patients.
• Whether the FDA grants SOMA Breakthrough Device designation.
• First long-term SOMA implants (company target late 2027) and where they happen.
• Neuralink's own next update. Its last company post was Oct 1 (decoder pretraining).

Video note

MTS's interview with Coherence CEO Ben Woodington (tAAw-lAAslU, uploaded Thu Oct 22, 9:00 AM ET) is the company making its case. Treat it as the claim, not the proof. Alternate: Huberman Lab Essentials with Neuralink's Dr. Matthew MacDougall (YdIJW8RTptU, Oct 15), an edited cut of an earlier conversation, not new reporting. The facts here come from the announcement and the written reports.